Stocks · News reference

Reported Earlier, CG Oncology's Phase 3 BOND-003 Cohort C Data Published In The Lancet Oncology, Showing 75.5% Complete Response Rate In BCG-Unresponsive Bladder Cancer

Jul 28, 2026, 7:38 AMBenzinga Newsdesk

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

Keep reading

Globenewswire IncSep 2, 2026, 12:00 PMNa
CG Oncology to Present at Upcoming Investor Conferences in September
CG Oncology announced that its CEO Arthur Kuan will participate in fireside chat presentations at the Cantor Fitzgerald Global Healthcare Conference on September 9, 2026, and the Morgan Stanley Global Healthcare Conference on September 14, 2026. The company is a late-stage clinical biopharmaceutical firm developing immunotherapies for bladder cancer treatment.
CGON
BenzingaAug 7, 2026, 6:38 PMBenzinga Newsdesk
RBC Capital Maintains Outperform on CG Oncology, Lowers Price Target to $79
CGON
BenzingaAug 7, 2026, 4:54 PMBenzinga Newsdesk
Piper Sandler Maintains Overweight on CG Oncology, Raises Price Target to $85
Piper Sandler analyst Kelsey Goodwin maintains CG Oncology (NASDAQ:CGON) with a Overweight and raises the price target from $82 to $85.
CGON
BenzingaAug 7, 2026, 1:12 PMBenzinga Newsdesk
Truist Securities Maintains Buy on CG Oncology, Raises Price Target to $85
Truist Securities analyst Gregory Renza maintains CG Oncology (NASDAQ:CGON) with a Buy and raises the price target from $82 to $85.
CGON